EBM Conference–Pediatrics
Emollient for prevention of eczema
Article: Lancet. 2020 Mar 21;395(10228):962-972. “Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial“ Reviewer: Dr. Tyler Emery …
The role of airway clearance treatments in CF patients on modulators
Article: Lancet Respir Med. 2023 Apr;11(4):329-340. “Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis…
Oral lactase for colic
Article: BMC Pediatr. 2022 Aug 3;22(1):468. “Oral lactase for infantile colic: a randomized double-blind placebo-controlled trial” Reviewer: Dr. Makayla Goggins…
Appendectomy vs. antibiotics for uncomplicated appendicitis
Article: Lancet. 2025 Jan 18;405(10474):233-240. “Appendicectomy versus Antibiotics for Acute Uncomplicated Appendicitis in Children“ Reviewer: Dr. Kamakshi Vaidyanathan …
Caffeine for apnea of prematurity
Article: New England Journal of Medicine. 2006 May 18;354(20):2112-21. “Caffeine therapy for apnea of prematurity” Reviewer: Dr. Parker Weigle …
Propranolol vs Atenolol in Infants with Hemangioma
Article: JAMA otolaryngology– head & neck surgery. 2021 Jul 1;147(7):599-607. “Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile…
Midline vs. Peripheral IV Catheters in Longer Term Pediatric Patients
Article: JAMA Pediatrics. 2023 Nov 1;177(11):1132-1140. “Midline Compared With Peripheral Intravenous Catheters for Therapy of 4 Days or Longer in Pediatric Patients….
Eat Sleep Console for Opioid Withdrawal
Article: N Engl J Med. 2023 Jun 22;388(25):2326-2337. Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal Reviewer: Dr. Stephen…
Shorter tuberculosis treatment in children
Article: N Engl J Med. 2022 Mar 10;386(10):911-922. “Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.” Reviewer: Dr. Brenden Stealey…
Dupilumab for Eosinophilic Esophagitis
Article: Lancet Gastroenterol Hepatol. 2023 Nov;8(11):990-1004. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis…